* This is the Professional Version. *
Acinetobacter sp can cause suppurative infections in any organ system; these bacteria are often opportunists in hospitalized patients.
Acinetobacter are gram-negative aerobic bacilli that belong to the family Neisseriaceae. They are ubiquitous and can survive on dry surfaces for up to a month and are commonly carried on the skin of health care workers, increasing the likelihood of patients being colonized and medical equipment being contaminated. There are many species of Acinetobacter; all can cause human disease, but A. baumannii (AB) accounts for about 80% of infections.
AB infections typically occur in critically ill, hospitalized patients. Community-acquired infections are more common in tropical climates. Crude death rates associated with AB infection are 19 to 54%.
The most common site for infection is the respiratory system. Acinetobacter easily colonize tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults. Hospital-acquired Acinetobacter pneumonias are frequently multilobar and complicated. Secondary bacteremia and septic shock are associated with a poor prognosis.
Acinetobacter sp can also cause suppurative infections (eg, abscesses) in any organ system, including the lungs, urinary tract, skin, and soft tissues; bacteremia may occur. Rarely, these organisms cause meningitis (primarily after neurosurgical procedures), cellulitis, or phlebitis in patients with an indwelling venous catheter; ocular infections; native or prosthetic valve endocarditis; osteomyelitis; septic arthritis; and pancreatic and liver abscesses.
The significance of isolates from clinical specimens is difficult to determine because they often represent colonization.
Risk factors for infection depend on the type of infection (hospital-acquired, community-acquired, multidrug resistant—see Table: Risk Factors for Acinetobacter Infection).
Risk Factors for Acinetobacter Infection
Recently, multidrug resistant (MDR) AB has emerged, particularly in ICUs in immunosuppressed patients, patients with serious underlying disorders, and patients treated with broad-spectrum antibiotics after an invasive procedure. Spread in ICUs has been attributed to colonized health care practitioners, contaminated common equipment, and contaminated parenteral nutrition solutions.
In patients with localized cellulitis or phlebitis associated with a foreign body (eg, IV catheter, suture), removal of the foreign body plus local care is usually sufficient. Tracheobronchitis after endotracheal intubation may resolve with pulmonary toilet alone. Patients with more extensive infections should be treated with antibiotics and with debridement if necessary.
AB has long had intrinsic resistance to many antimicrobials. MDR-AB are defined as strains that are resistant to ≥ 3 classes of antimicrobials; some isolates are resistant to all. Before susceptibility results are available, possible initial options include a carbapenem (eg, meropenem, imipenem, doripenem), colistin, or a fluoroquinolone plus an aminoglycoside, rifampin, or both. Sulbactam (a β-lactamase inhibitor) has intrinsic bactericidal activity against many MDR-AB strains. Tigecycline, a glycylcycline antibiotic, is also effective; however, borderline activity and emergence of resistance during therapy have been reported.
Mild to moderate infections may respond to monotherapy. Traumatic wound infections can be treated with minocycline. Serious infections are treated with combination therapy—typically, imipenem, or ampicillin/sulbactam plus an aminoglycoside.
To prevent spread, health care practitioners should use contact precautions (hand washing, barrier precautions) and appropriate ventilator care and cleaning for patients colonized or infected with MDR-AB.
A. baumannii (AB) accounts for about 80% of infections and tends to occur in critically ill, hospitalized patients.
The most common site for infection is the respiratory system, but Acinetobacter sp can also cause suppurative infections in any organ system.
Multidrug-resistant AB has become a problem; use multidrug treatment chosen based on susceptibility testing.
Drug NameSelect Brand Names
ampicillinNo US brand name
* This is the Professional Version. *